Improving Outcomes in Patients with Small Cell Lung Cancer Through Improved Therapeutic Selection
Improving Outcomes in Patients with Small Cell Lung Cancer Through Improved Therapeutic Selection
EDWARD B. GARON, MD, MS
Associate Professor of Medicine and Hematology-Oncology
Director, Thoracic Oncology Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
JONATHAN GOLDMAN, MD
Associate Professor of Hematology-Oncology
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, California
STEPHEN V. LIU, MD
Associate Professor of Medicine
Director, Thoracic Oncology and Developmental Therapeutics
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia
Provided by North American Center for Continuing Medical Education, LLC (NACCME), an HMP Company.
For questions regarding this educational activity, please call 609-371-1137 or email info@naccme.com.
This activity is designed for a national audience of multidisciplinary team members, including medical oncologists, community oncologists, pathologists, oncology pharmacists, health-system pharmacists, oncology nurses, nurse practitioners, physician assistants, and other clinicians involved and/or interested in the therapeutic management of patients with thoracic malignancies.
Thoracic malignancies—such as small cell lung cancer (SCLC)—are not only the most common cancers, but the leading cause of cancer-related deaths in the United States. Although incidences and mortality rates have gradually declined, only 18% of patients survive 5+ years after diagnosis, with stage at diagnosis strongly influencing survival. The landscape of thoracic oncology is rapidly evolving to reflect advances in diagnostic, prognostic, and staging capabilities. These include the identification of key biomarkers that aid in treatment selection and prognosis, novel surgical methods, and a wave of new and emerging treatment approaches that target particular genetic aberrations or harness the patient’s own immune system, innovations that now offer a tailored approach to care and improved outcomes. The continual progress and growing complexity within this field create a clinical conundrum for medical oncologists and thoracic oncology care teams to remain up to date on the latest developments and how to best integrate them into clinical practice.
SCLC is an area of particular need, with dismal survival rates and few therapeutic options. However, a recent surge in treatments has rapidly changed the standard of care for this underserved disease, providing patients with a glimmer of hope. This surge of approvals and late-stage trials comes with a mandate for clinicians to remain up to date on evolving and emerging treatment strategies and the latest clinical data to inform patient and treatment selection. Additionally, new therapeutic classes come with new sets of challenges to navigate. Oncology clinicians throughout the US must be prepared to integrate these novel agents into clinical practice for patients with SCLC.
This webcast aims to fill the gaps surrounding novel treatment selection for patients with small cell lung cancer.
After participating in this activity, learners should be better able to:
-
Analyze barriers to the optimal management of limited-stage SCLC
- Evaluate the latest data concerning the safety and efficacy of available and emerging single agent and combination treatment approaches for extensive-stage SCLC
- Delineate the pathophysiology of SCLC, the mechanisms leading to relapsed and refractory disease, and the role of second- and third-line agents in this setting
To be eligible for credit, participants must complete the online activity and the evaluation. Upon completing the activity, there will be instructions on how to complete the evaluation and print a certificate or other documentation of credit.
Release Date: December 15, 2020
Expiration Date: December 15, 2021
Estimated Time to Complete: 1.25 hours
There is no fee associated with this activity.
Supported by educational grants from Ipsen Biopharmaceuticals, Inc. and Jazz Pharmaceuticals.
In support of improving patient care, NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates this internet enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing nursing education activity awards 1.25 contact hours.
Provider approved by the California Board of Registered Nursing, Provider #13255 for 1.25 contact hours.
American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
This internet enduring, knowledge-based activity (Universal Activity Number:JA0006201-0000-20-237-H01-P) has been approved for a maximum of 1.25 contact hours (.125 CEUs).
The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. Following ACPE Policy, NACCME must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity. NACCME is not able to report your claimed credit after this 60-day period. Eligibility for pharmacy credit is contingent upon the successful completion of a post-test and/or evaluation for each activity or session attended.
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 credits. PAs should only claim credit commensurate with the extent of their participation.
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.
According to the disclosure policy of NACCME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME to initiate a mechanism to resolve the conflict. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
Planning Committee
In addition to the faculty listed below, NACCME planners and staff include Samantha Conforti, Mary Johnson, Randy Robbin, Greaton Sellers, Shannon Stevenson, and Griselda Zuccarino-Catania.
No planner has disclosed a relevant financial relationship with any commercial interest.
Faculty
The faculty has reported the following:
Edward Garon: Advisory Board-GlaxoSmithKline, Merck, Novartis, Shiogi; Grant/Research Support-AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, EMD SERONO, Genentech, Iovance, Merck, Mirati, Neon Therapeutics, Novartis.
Jonathan Goldman: Advisory Board-AstraZeneca, Genentech, Jazz Pharmaceuticals; Consultant-AstraZeneca, Genentech; Grant/Research Support-Array/Pfizer, AstraZeneca, Genentech, GlaxoSmithKline, Merck.
Stephen Liu: Advisory Board-AstraZeneca, Blueprint Medicines Corporation, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Lilly, PharmaMar, Regeneron; Consultant-AstraZeneca, Celgene, Genentech/Roche, Janssen, Merck; Editorial Support-Boehringer Ingelheim; Grant/Research Support-Alkermes, AstraZeneca, Bayer, Blueprint Medicines Corporation, Bristol-Myers Squibb, Genentech/Roche, Janssen, Lilly, Merck, Molecular Partners, Pfizer, Rain Therapeutics, RAPT, Spectrum, Turning Point Therapeutics.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and our joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2020 by North American Center for Continuing Medical Education, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education.
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please call 609-371-1137.
Any participant wanting to file a grievance with respect to any aspect of a continuing education activity accredited by NACCME, LLC may contact Samantha Conforti, Manager, Accreditation and Compliance, by phone at 609-371-1137, by email at sconforti@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520. The Manager, Accreditation and Compliance will review the grievance and respond within 30 days of receiving the complaint. If the participant is unsatisfied with the response, an appeal to the Associate Director, Greaton Sellers, Accreditation and Compliance, can be requested for a second level of review. Mr. Sellers can be contacted via phone at 609-371-1137, by email at gsellers@naccme.com or in writing at 104 Windsor Center Drive, East Windsor, NJ 08520.
